Antiangiogenic	0	14	O
and	15	18	O
antitumor	19	28	B-Pathological_formation
effects	29	36	O
of	37	39	O
a	40	41	O
protein	42	49	B-Gene_or_gene_product
kinase	50	56	I-Gene_or_gene_product
Cbeta	57	62	I-Gene_or_gene_product
inhibitor	63	72	O
in	73	75	O
human	76	81	B-Organism
breast	82	88	B-Pathological_formation
cancer	89	95	I-Pathological_formation
and	96	99	O
ovarian	100	107	B-Pathological_formation
cancer	108	114	I-Pathological_formation
xenografts	115	125	I-Pathological_formation
.	125	126	O

In	128	130	O
cell	131	135	B-Cell
culture	136	143	O
,	143	144	O
the	145	148	O
compound	149	157	O
317615	158	164	B-Drug_or_compound
2HCl	165	169	I-Drug_or_compound
,	169	170	O
a	171	172	O
potent	173	179	O
inhibitor	180	189	O
of	190	192	O
VEGF	193	197	B-Gene_or_gene_product
-	197	198	O
stimulated	198	208	O
HUVEC	209	214	B-Cell
proliferation	215	228	O
,	228	229	O
was	230	233	O
not	234	237	O
very	238	242	O
effective	243	252	O
against	253	260	O
MX	261	263	B-Cell
-	263	264	I-Cell
1	264	265	I-Cell
breast	266	272	I-Cell
cancer	273	279	I-Cell
cells	280	285	I-Cell
(	286	287	O
IC50	287	291	O
=	291	292	O
8	293	294	O
.	294	295	O
1	295	296	O
microM	297	303	O
)	303	304	O
or	305	307	O
SKOV	308	312	B-Cell
-	312	313	I-Cell
3	313	314	I-Cell
ovarian	315	322	I-Cell
carcinoma	323	332	I-Cell
cells	333	338	I-Cell
(	339	340	O
IC50	340	344	O
=	345	346	O
9	347	348	O
.	348	349	O
5	349	350	O
microM	351	357	O
)	357	358	O
.	358	359	O

Exposure	360	368	O
to	369	371	O
combinations	372	384	O
of	385	387	O
paclitaxel	388	398	B-Drug_or_compound
or	399	401	O
carboplatin	402	413	B-Drug_or_compound
and	414	417	O
317615	418	424	B-Drug_or_compound
x	425	426	I-Drug_or_compound
2HCl	427	431	I-Drug_or_compound
with	432	436	O
MX	437	439	B-Cell
-	439	440	I-Cell
1	440	441	I-Cell
cells	442	447	I-Cell
in	448	450	O
culture	451	458	O
resulted	459	467	O
in	468	470	O
cell	471	475	B-Cell
survival	476	484	O
that	485	489	O
reflected	490	499	O
primarily	500	509	O
additivity	510	520	O
of	521	523	O
the	524	527	O
two	528	531	O
agents	532	538	O
.	538	539	O

Exposure	540	548	O
of	549	551	O
SKOV	552	556	B-Cell
-	556	557	I-Cell
3	557	558	I-Cell
cells	559	564	I-Cell
to	565	567	O
paclitaxel	568	578	B-Drug_or_compound
or	579	581	O
carboplatin	582	593	B-Drug_or_compound
along	594	599	O
with	600	604	O
317615	605	611	B-Drug_or_compound
2HCl	612	616	I-Drug_or_compound
resulted	617	625	O
in	626	628	O
cell	629	633	B-Cell
survivals	634	643	O
that	644	648	O
reflected	649	658	O
additivity	659	669	O
of	670	672	O
317615	673	679	B-Drug_or_compound
x	680	681	I-Drug_or_compound
2HCl	682	686	I-Drug_or_compound
with	687	691	O
paclitaxel	692	702	B-Drug_or_compound
and	703	706	O
greater	707	714	O
-	714	715	O
than	715	719	O
-	719	720	O
additive	720	728	O
cytotoxicity	729	741	O
with	742	746	O
carboplatin	747	758	B-Drug_or_compound
.	758	759	O

Administration	760	774	O
of	775	777	O
317615	778	784	B-Drug_or_compound
x	785	786	I-Drug_or_compound
2HCI	787	791	I-Drug_or_compound
orally	792	798	O
twice	799	804	O
daily	805	810	O
to	811	813	O
nude	814	818	B-Organism
mice	819	823	I-Organism
bearing	824	831	O
subcutaneous	832	844	O
MX	845	847	B-Pathological_formation
-	847	848	I-Pathological_formation
1	848	849	I-Pathological_formation
tumors	850	856	I-Pathological_formation
or	857	859	O
SKOV	860	864	B-Pathological_formation
-	864	865	I-Pathological_formation
3	865	866	I-Pathological_formation
tumors	867	873	I-Pathological_formation
resulted	874	882	O
in	883	885	O
a	886	887	O
decreased	888	897	O
number	898	904	O
of	905	907	O
intratumoral	908	920	B-Multi-tissue_structure
vessels	921	928	I-Multi-tissue_structure
as	929	931	O
determined	932	942	O
by	943	945	O
CD31	946	950	B-Gene_or_gene_product
and	951	954	O
CD105	955	960	B-Gene_or_gene_product
staining	961	969	O
with	970	974	O
decreases	975	984	O
of	985	987	O
35	988	990	O
%	990	991	O
and	992	995	O
43	996	998	O
%	998	999	O
in	1000	1002	O
MX	1003	1005	B-Pathological_formation
-	1005	1006	I-Pathological_formation
1	1006	1007	I-Pathological_formation
tumors	1008	1014	I-Pathological_formation
and	1015	1018	O
60	1019	1021	O
%	1021	1022	O
and	1023	1026	O
75	1027	1029	O
%	1029	1030	O
in	1031	1033	O
SKOV	1034	1038	B-Pathological_formation
-	1038	1039	I-Pathological_formation
3	1039	1040	I-Pathological_formation
tumors	1041	1047	I-Pathological_formation
,	1047	1048	O
respectively	1049	1061	O
.	1061	1062	O

317615	1063	1069	B-Drug_or_compound
x	1070	1071	I-Drug_or_compound
2HCl	1072	1076	I-Drug_or_compound
was	1077	1080	O
an	1081	1083	O
active	1084	1090	O
antitumor	1091	1100	B-Pathological_formation
agent	1101	1106	O
against	1107	1114	O
the	1115	1118	O
MX	1119	1121	B-Pathological_formation
-	1121	1122	I-Pathological_formation
1	1122	1123	I-Pathological_formation
xenograft	1124	1133	I-Pathological_formation
and	1134	1137	O
increased	1138	1147	O
the	1148	1151	O
tumor	1152	1157	B-Pathological_formation
growth	1158	1164	O
delay	1165	1170	O
produced	1171	1179	O
by	1180	1182	O
paclitaxel	1183	1193	B-Drug_or_compound
by	1194	1196	O
1	1197	1198	O
.	1198	1199	O
7	1199	1200	O
-	1200	1201	O
fold	1201	1205	O
and	1206	1209	O
the	1210	1213	O
tumor	1214	1219	B-Pathological_formation
growth	1220	1226	O
delay	1227	1232	O
produced	1233	1241	O
by	1242	1244	O
carboplatin	1245	1256	B-Drug_or_compound
by	1257	1259	O
3	1260	1261	O
.	1261	1262	O
8	1262	1263	O
-	1263	1264	O
fold	1264	1268	O
.	1268	1269	O

Administration	1270	1284	O
of	1285	1287	O
317615	1288	1294	B-Drug_or_compound
x	1295	1296	I-Drug_or_compound
2HCl	1297	1301	I-Drug_or_compound
also	1302	1306	O
increased	1307	1316	O
the	1317	1320	O
tumor	1321	1326	B-Pathological_formation
growth	1327	1333	O
delay	1334	1339	O
produced	1340	1348	O
by	1349	1351	O
fractionated	1352	1364	O
radiation	1365	1374	O
therapy	1375	1382	O
in	1383	1385	O
the	1386	1389	O
MX	1390	1392	B-Pathological_formation
-	1392	1393	I-Pathological_formation
1	1393	1394	I-Pathological_formation
tumor	1395	1400	I-Pathological_formation
.	1400	1401	O

Treatment	1402	1411	O
with	1412	1416	O
317615	1417	1423	B-Drug_or_compound
x	1424	1425	I-Drug_or_compound
2HCl	1426	1430	I-Drug_or_compound
alone	1431	1436	O
increased	1437	1446	O
the	1447	1450	O
lifespan	1451	1459	O
of	1460	1462	O
animals	1463	1470	O
bearing	1471	1478	O
intraperitoneal	1479	1494	O
SKOV	1495	1499	B-Pathological_formation
-	1499	1500	I-Pathological_formation
3	1500	1501	I-Pathological_formation
xenografts	1502	1512	I-Pathological_formation
by	1513	1515	O
1	1516	1517	O
.	1517	1518	O
9	1518	1519	O
fold	1520	1524	O
compared	1525	1533	O
with	1534	1538	O
untreated	1539	1548	O
control	1549	1556	O
animals	1557	1564	O
.	1564	1565	O

The	1566	1569	O
combination	1570	1581	O
of	1582	1584	O
paclitaxel	1585	1595	B-Drug_or_compound
and	1596	1599	O
317615	1600	1606	B-Drug_or_compound
x	1607	1608	I-Drug_or_compound
2HCl	1609	1613	I-Drug_or_compound
resulted	1614	1622	O
in	1623	1625	O
100	1626	1629	O
%	1629	1630	O
120	1631	1634	O
-	1634	1635	O
day	1635	1638	O
survival	1639	1647	O
of	1648	1650	O
SKOV	1651	1655	B-Pathological_formation
-	1655	1656	I-Pathological_formation
3	1656	1657	I-Pathological_formation
bearing	1658	1665	O
animals	1666	1673	O
.	1673	1674	O

Administration	1675	1689	O
of	1690	1692	O
317615	1693	1699	B-Drug_or_compound
x	1700	1701	I-Drug_or_compound
2HCl	1702	1706	I-Drug_or_compound
along	1707	1712	O
with	1713	1717	O
carboplatin	1718	1729	B-Drug_or_compound
to	1730	1732	O
animals	1733	1740	O
bearing	1741	1748	O
the	1749	1752	O
SKOV	1753	1757	B-Pathological_formation
-	1757	1758	I-Pathological_formation
3	1758	1759	I-Pathological_formation
tumor	1760	1765	I-Pathological_formation
produced	1766	1774	O
a	1775	1776	O
1	1777	1778	O
.	1778	1779	O
8	1779	1780	O
-	1780	1781	O
fold	1781	1785	O
increase	1786	1794	O
in	1795	1797	O
lifespan	1798	1806	O
compared	1807	1815	O
with	1816	1820	O
carboplatin	1821	1832	B-Drug_or_compound
alone	1833	1838	O
.	1838	1839	O

317615	1840	1846	B-Drug_or_compound
x	1847	1848	I-Drug_or_compound
2HCl	1849	1853	I-Drug_or_compound
is	1854	1856	O
a	1857	1858	O
promising	1859	1868	O
new	1869	1872	O
antiangiogenic	1873	1887	O
agent	1888	1893	O
that	1894	1898	O
is	1899	1901	O
in	1902	1904	O
early	1905	1910	O
phase	1911	1916	O
clinical	1917	1925	O
testing	1926	1933	O
.	1933	1934	O

